First-in-Human VCAS Trial Results with FieldForce™ Ablation System Published in Circulation

Results from the first-in-human Ventricular Catheter Ablation Study (VCAS) evaluating Field Medical’s FieldForce™ Ablation System have been published in Circulation. The peer-reviewed article reports six-month outcomes demonstrating 82% freedom from VT/VF recurrence or ICD therapy and a 98% reduction in ventricular arrhythmia burden, marking an important clinical milestone in pulsed field ablation for ventricular tachycardia.

Read the full press release here.